GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Cyclically Adjusted Revenue per Share

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Cyclically Adjusted Revenue per Share : ¥7.26 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Wuhan Easy Diagnosis Biomedicine Co's adjusted revenue per share data for the fiscal year that ended in Dec. 2023 was ¥3.301. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥7.26 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 61.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Wuhan Easy Diagnosis Biomedicine Co was 61.30% per year. The lowest was 61.30% per year. And the median was 61.30% per year.

As of today (2024-06-22), Wuhan Easy Diagnosis Biomedicine Co's current stock price is ¥ 17.88. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2023 was ¥7.26. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio of today is 2.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wuhan Easy Diagnosis Biomedicine Co was 17.39. The lowest was 2.27. And the median was 11.47.


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Revenue per Share Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.73 2.92 7.31 7.26

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 7.26 -

Competitive Comparison of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio falls into.



Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wuhan Easy Diagnosis Biomedicine Co's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.301/114.7809*114.7809
=3.301

Current CPI (Dec. 2023) = 114.7809.

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.406 99.000 0.471
201512 0.629 100.600 0.718
201612 0.912 102.600 1.020
201712 1.063 104.500 1.168
201812 0.998 106.500 1.076
201912 0.870 111.200 0.898
202012 4.597 111.500 4.732
202112 13.385 113.108 13.583
202212 45.814 115.116 45.681
202312 3.301 114.781 3.301

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Wuhan Easy Diagnosis Biomedicine Co  (SZSE:002932) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.88/7.26
=2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Wuhan Easy Diagnosis Biomedicine Co was 17.39. The lowest was 2.27. And the median was 11.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Executives
Wang Rui Directors, executives
Wang Jian Fei Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines